Kirkland Advises Apogee Therapeutics on $10.9 Billion Sale to Abbvie

Kirkland & Ellis advised Apogee Therapeutics (Nasdaq: APGE) on a definitive agreement under which AbbVie (NYSE: ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie's clinical presence in the respiratory space. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. The transaction values Apogee at a total equity value of approximately $10.9 billion. The boards of directors of both companies have unanimously approved the transaction. This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.

Read the transaction press release

The Kirkland team included corporate lawyers Graham Robinson and Chadé Severin; technology & IP transactions lawyers Shellie Freedman and Rami Sherman; antitrust & competition lawyer Maria Raptis; and executive compensation lawyer Tim Nelson.